Neurocysticercosis presenting as psychosis: A case report and a brief literature review

Saeed Ahmed1, Sadia Usmani2, Sana Javed3, Aakash Hans4, Sundas Saboor5, Aunsa Hanif6, Sheikh Mohd Saleem7 and Sheikh Shoib8

Abstract
Patients with neurocysticercosis, a common infection of the central nervous system caused by Taenia solium, have been reported to develop neuropsychiatric complications. We report a unique case of recurrent psychosis caused by neurocysticercosis in a 37-year-old El Salvador immigrant woman and discuss the underlying pathophysiological mechanisms of the complications. We reviewed published case reports of neurocysticercosis that presented with psychotic features and compared their diagnostic evaluation, the underlying pathophysiology of complications and treatment regimen with our case. This review concludes that neurocysticercosis should be considered in the differential diagnosis of patients presenting with psychosis with a history of residence in an endemic area.

Keywords
Neurocysticercosis, psychosis, psychotic manifestations, hallucinations, delusions

Date received: 11 October 2021; accepted: 22 April 2022

Introduction
Neurocysticercosis (NCC) is the most severe form of cysticercosis to cause infection of the central nervous system (CNS) and is the leading cause of acquired epilepsy in humans globally.1 The total number of individuals suffering from NCC is about 2.56–8.30 million worldwide, while it is estimated that the total symptomatic cases in endemic regions are roughly 400,000.1 NCC is endemic in Latin America, Asia, Africa and Central Europe, where 30% of all epilepsy cases are caused by it.2 Recently, it is being diagnosed more often in the United States due to increased migration.3 However, very little attention has been paid to its surveillance, prevention and treatment.4

NCC is caused by the feco-oral transmission of Taenia solium eggs. Humans ingest these parasite eggs, and their embryos invade the mucosa of the small intestine, from where they enter the circulation and subsequently into the CNS.5 NCC is classified into six clinical syndromes: asymptomatic, parenchymal, intraventricular, subarachnoid, spinal and ocular forms.5 Clinical manifestations of NCC depend on the location of the lesions and the number of cysts; however, commonly associated neurological symptoms are chronic headache, increased intracranial hypertension (ICH) with symptoms of vomiting, nausea, dizziness and changes in vision and focal neurological deficits.3 NCC may also cause psychiatric manifestations like depression and psychosis.5 In psychosis, a person loses contact with reality; symptoms include delusions, hallucinations, bizarre behavior and incoherent speech.7

Psychosis is a rare presenting complaint in NCC. One in twenty NCC patients present with psychosis, and only 5% of NCC patients present with psychosis in the emergency department (ED)6 (2004). NCC remains underdiagnosed in most patients as it is asymptomatic in approximately 50% of cases.8 The variability in its clinical presentation and neuropathology makes it challenging to diagnose, highlighting the importance of thorough history taking, early detection and
treatment. In this literature review, we present a rare case of recurrent psychosis, along with a detailed review of previous case reports of psychotic presentation with NCC, along with associated features, diagnostic evaluation and treatment options. This review will help clinicians recognize and treat NCC presenting with psychotic symptoms.

Case presentation

A 37-year-old female immigrant from El Salvador presented with a headache, strange behavior, auditory hallucinations and paranoid delusions to the ED. She admitted to being depressed, having a decreased appetite, sleep deprivation and forgetfulness. She was admitted to the medical floor to rule out delirium, and the consultation–liaison (CL) team was contacted. When the CL team saw the patient, she was still paranoid, delusional and experiencing auditory hallucinations. A review of systems revealed no evidence of a focal neurological deficit. The general physical examination revealed no abnormalities. On mental status examination, her appearance was unkempt; the behavior was strange with poor eye contact. She described her mood as “depressed,” and her affect was constricted. Her thought process was concrete with circumstantiality at times; thought content was positive for paranoid delusions, “her husband making plans with his girlfriend to murder his wife and daughters.” On perceptions disturbances, she was positive for auditory hallucinations. She lacked insight/judgment, but her orientation and memory were intact. The Mini Mental State Examination (MMSE)\(^9,^{10}\) score was 27. The CL team began her on risperidone 1 mg two times a day (BID) targeting psychotic symptoms. Collateral history revealed that the patient had a history of generalized tonic–clonic seizures (GTCs), for which an antiepileptic medication was started. During the same period, she was diagnosed with NCC and was prescribed albendazole 400 mg BID for 28 days, but she did not take the medication due to a lack of insurance. During the current hospitalization, the medical team obtained a computed tomography (CT) scan and a magnetic resonance imaging (MRI) of the brain. The CT brain indicated hypodense regions in the right frontal and parietal lobes, as well as abnormal and irregular calcifications (Figure 1). The MRI revealed encephalomalacia in the upper right frontal and parietal lobes, as well as a rim of adjacent gliosis. On the following day of her admission, she was cleared by the medical team and transferred to psychiatry for psychosis. Risperidone was increased to 6 mg/day in two divided doses of 3 mg BID due to the patient’s persistent psychotic symptoms. After her psychosis had resolved, she was discharged with an aftercare follow-up appointment at a nearby facility.

Discussion

This article aims to highlight the difficulties in diagnosing and treating NCC in patients with psychosis in the United States or other NCC-prevalent countries. In addition to the case, presented here, we conducted a literature review of 21 similar cases (Table 1). Thirteen case reports came from India, the remaining instances came from Nepal, Brazil, Haiti, Portugal and Africa. Thirteen were male, and eight were female. Fifteen cases were between the ages of 21 and 50 years, four were between the ages of 10 and 20 years, and two were elderly (>51 years). The current case was diagnosed with NCC and presented to the ED with psychosis in 2017. However, due to non-compliance, she explained to the ED again after 3 years with psychosis. This demonstrates a high probability of recurrence of NCC if the disease is not treated optimally or if patients do not adhere to their recommended medication. Cases were reported in the literature where patients were non-compliant and presented with psychosis, most likely due to reinfection.\(^{16,25,29}\) In NCC, psychiatric symptoms may be triggered by inflammatory injury to the brain caused by degenerating cysts and mechanical alterations in cerebrospinal fluid (CSF) pressure.\(^6\) The classification of psychiatric manifestations is based on the location of the lesion\(^6\) (Table 2). The parietal lobe is involved in many neuropsychological functions, including its engagement...
| Author                          | Case report                                                                 | First presentation | Second presentation | Third presentation | Fourth presentation | Outcome                                                                 |
|--------------------------------|-------------------------------------------------------------------------------|--------------------|---------------------|--------------------|--------------------|-------------------------------------------------------------------------|
| Shriqui and Milette, 1992²⁸    | You drive me crazy: a case report of acute psychosis and neurocysticercosis | First admission to hospital: Low dose of haloperidol with close supervision, subsequently increased to 15 mg daily and then 2 mg. Steroids were administered, tapered off and discontinued after 1 month. Continuation of haloperidol 2 mg. | No treatment: | | | Resolution of her nausea, vomiting and headache. Her gait also improved significantly. Follow-up, MMSE increased significantly. Improvement in her incontinence. |
| Bills and Symon, 1992²⁶       | Cysticercosis producing various neurological presentations in a patient: case report | First presentation: 2 weeks trial of praziquantel. Steroids were administered, tapered off and then discontinued after 1 month. Continuation of haloperidol 2 mg. | Antipsychotic medication. Steroids (presuming it was encephalitis). | | | Psychosis improved within 2 weeks along with improvement of MMSE scores. Able to do perform independently after 6 months. |
| Verma and Kumar, 2013³⁰       | Neurocysticercosis presenting as acute psychosis: a rare case report from rural India | Steroid (prednisolone) 1 mg/kg of body weight. Acetazolamide 250 mg twice daily. Antipsychotic drugs olanzapine 20 mg/day and clonazepam 2/day. | No treatment: | | | Free of seizures and psychiatric symptoms on follow-up. |
| Mahajan et al., 2004⁶         | Neurocysticercosis presenting with psychosis | Antipsychotic drugs risperidone 4 mg/day and clonazepam 2 mg/day. Steroid (prednisolone) 50 mg/kg/day for 2 weeks. Praziquantel (50 mg/kg/day) for 2 weeks. | Reversion of ventriculoperitoneal shunt after 2 months. | | | Free of seizures and psychiatric symptoms on follow-up. |
| Singh et al., 2004⁴           | An unusual cause of psychosis (2004) | Antipsychotic drugs olanzapine 10 mg/day with venlafaxine 75 mg/day (as psychotic symptoms worsened). | Prednisone for 28 days and acetazolamide for 2 months. | | | Free of seizures and psychiatric symptoms on follow-up. |
| Anjana et al., 2020²³         | An unusual presentation of neurocysticercosis as psychosis with tics | | | | | Improved and regained pre-morbid lucidity. |
| Author          | Case report                                                                 | Psychosis treatment                                                                 | Treatment duration | Outcome                                                                                       |
|-----------------|------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|--------------------|---------------------------------------------------------------------------------------------|
| Sarangi et al., 2013 | Neurocysticercosis masquerading psychotic disorder: a case report             | Albendazole (15 mg/kg/day) for 7 days. Prednisolone (2 mg/kg/day) for 7 days. Valproate.    | 7 days.             | Discharged on valproate. At 3 months follow-up, there was a significant decrease in psychotic symptoms and resolution of CT scan lesions. |
| da Silva Miranda et al., 2020 | Neurocysticercosis presenting as acute psychosis: an unusual case            | Albendazole for 1 month. Corticosteroid for 1 month. Aripiprazole (to be continued).    | 1 month.           | Improvement after 1 month, but developed psychotic symptoms after discontinuation of antipsychotic therapy with several relapses due to non-compliance. |
| Thapa et al., 2016 | Neurocysticercosis presented with acute psychosis: a case report             | Antipsychotics and sedatives to control symptoms. Albendazole 400 mg twice daily for 4 weeks. Steroids. Sodium valproate (was started due to onset of GTCS-1 episode). | 4 weeks.           | One episode of GTCS during treatment for which valproate was initiated. Symptoms improved and the patient recovered completely after a few days. |
| Verma et al., 2011 | Neurocysticercosis association with cognitive and aberrant behavioral symptoms: a case report and review | Medications records not available.                                                    | Unknown            | Treatment did not help in patient improvement, and only led to increased sleep.              |
| Mishra and Swain, 2004 | Psychiatric morbidity following neurocysticercosis                           | First treatment: Haloperidol PO. Carbamazepine. Supervision: Second treatment (after 12 weeks): Haloperidol, Carbamazepine, Diazepam, Praziquantel, Steroid. | First treatment duration: 6 weeks. Second treatment duration: Unknown. | Complete recovery. |
| Bhatia et al., 1994 | Neurocysticercosis presenting as schizophrenia: a case report               | Haloperidol 20 mg/dL. Phenytoin 300 mg/day in divided doses. Haloperidol 15 mg/kg/day in divided doses. Haloperidol 30 mg/day. | First treatment duration: 3 weeks. Second treatment duration: 4 weeks—haloperidol was tapered and completely stopped after 3 months. | No improvement in behavior with first treatment. With the second treatment, CT scan at 3 months showed a decrease in number of pinhead lesions, but persistent calcified lesions. Complete recovery in 4 months. |
| Elemanalili et al., 2017 | Neurocysticercosis presenting with psychosis Racemose neurocysticercosis with psychiatric symptoms: a case report | Anthelmintic, antipsychotic and steroids.                                              | Unknown.           | Symptoms improved. |
| Reis et al., 2014 |                                                                                  | Albendazole.                                                                         | 28 days.           | Complete resolution of psychiatric symptoms, regression of lesions on CT scan at day 23.    |
| Author                      | Case report                                                                 | Psychosis treatment                                                                 | Treatment duration | Outcome                                                                 |
|-----------------------------|------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|-------------------|------------------------------------------------------------------------|
| Bourgeois et al., 200224    | Mood and psychotic symptoms with neurocysticercosis                          | Drainage of the right temporal lobe cyst and trapped ventricle was performed. Rifampin, vancomycin and albendazole prescribed. Risperidone 0.5 mg BID. | 12 days.          | Feeling less depressed at 12 days after admission. Neuro-vegetative symptoms improved. No delusions nor hallucinations. Her MMSE score improved. |
| Gournellis et al., 201916   | A case of neurocysticercosis: neuropsychiatric manifestations, course and treatment | Initially treated with haloperidol 2 mg TID and valproic acid 600 mg TID. Haloperidol was stopped and olanzapine 5mg/OD was started. Long-acting injectable olanzapine 210 mg twice a month in monotherapy before discharge. | 18 days.          | Five-year follow-up period, the patient presented cyclical periods of manic-like and depressive-like episodes lasting about 1 month each, with periods of 1/2 to 1 month of normothyemia in-between. |
| Reyazuddin M et al., 201418 | Acute psychosis: an unusual presentation in disseminated neurocysticercosis   | Albendazole 400 mg BID. Prednisone 60 mg OD. Antiepileptic medication. Haloperidol 5mg IM. | 7 days.           | Patient improved and medications were discontinued.                   |
| Mustafa et al., 202017      | Neuropsychiatric manifestations of neurocysticercosis                        | Albendazole 400 mg BID. Dexamethasone 2 mg IV TID. Intubated and shifted to the intensive care unit (ICU) for mechanical ventilation support. | Unknown.          | Patient expired.                                                      |
| Gariebballa and Hakam, 200812 | Neurocysticercosis presenting with psychiatric manifestations | Albendazole 500mg orally BID for 10 days. Dexamethasone 2mg BID for 7 days. Ranitidine 300mg OD for 5 days. Phenytoin 300mg orally QHS for 7 days. Lorazepam 2mg BID for 2 days, then 1mg BID for 3 days. | 3 days.           | Symptoms resolved; prescribed hydroxyzine 10mg BID for 4 weeks (to treat fear and anxiety). |
| Bhushan et al., 202015      | Neurocysticercosis presenting with acute and transient psychotic disorder: a case report | Risperidone 2mg QHS. Lorazepam 1mg BID. Valproate 500mg BID. | Unknown.          | Symptoms improved.                                                    |

OD: once a day; BID: two times a day; TID: three times a day; QID: four times a day; IV: intravenous; IM: intramuscular; MMSE: Mini-Mental State Examination; GTCS: generalized tonic–clonic seizure; QHS: every night at bedtime; CT: computed tomography.
with the frontal lobe to store and retrieve verbal information. Both the parietal and frontal lobes have solid anatomical connections and are activated simultaneously in performing cognitive tasks. In addition to changes in the cortical areas responsible for the normal physiological function of hearing and vision, the limbic system is also involved in developing psychotic phenomena such as auditory and visual hallucinations. However, limbic structures play a central role in the psychopathology of psychosis, involving frontal and parietal structures.

The case reports support the high frequency of neuropsychiatric symptoms in patients with NCC. Ms Ana had headaches with psychotic symptoms, as recorded in nine other case reports. Many intracranial infections cause headaches. Most headaches subside once the infection is resolved, but chronic post-infectious headaches can last for months. Infectious headaches require antimicrobial therapy due to viable microorganisms. People with calcified parenchymal brain cysticercosis are more likely to suffer from primary headache disorders than head trauma and cerebrovascular disease.

The current case suffered from depression, which was also reported in three other case reports. Depression generally accounts for 56.2% of NCC cases. It has been associated with various neurobiological mechanisms, such as changes in neural biology, abnormal neuronal adaptive capability, decreased neurotransmitter levels and endocrine variations. Neuroinflammation is also thought to cause depression. Although there is no established causal relationship between neuroinflammation and depression, studies show that neuroinflammation caused by various diseases alters an individual’s risk profile for developing depression either immediately or later in life.

One study examined the prevalence of depression in NCC patients. The researchers reported depression rates of 83% in the NCC group with epilepsy, 88% in the NCC without epilepsy group, 92% in epilepsy without NCC group and 100% in the epilepsy without headache group. The study found a link between moderate-intensity depression and chronic illnesses. Another study that measured the activity of NCC disease through total protein levels in the cerebrospinal fluid (CSF-TP) found an inverse relationship between NCC and the presence of depression, with patients with higher CSF-TP readings having minimal or no depression.

Seizures are NCC’s most common neurological manifestation in intraparenchymal, enhancing and discrete lesions. Nine cases had GTCSs, one had focal seizures, and one case report presented with partial seizures. Focal seizures occur when cysticercosis invades the temporal-limbic area of the cerebral cortex, whereas GTCS occurs when the cerebral cortex develops multiple parenchymal cysts and calcifications. GTCS is caused by changes in CSF pressure and inflammation in the brain’s frontal lobe. Similarly, genetic predispositions to seizures have been observed in patients with NCC. Matrix metallopeptidase-9 (MPP-9) is an enzyme involved in NCC calcified cysts, triggering seizures. Furthermore, Toll-like receptors (TLRs) are thought to be responsible for the brain’s immune response to NCC, resulting in seizures.

### Diagnostic imaging

Imaging modalities like CT (with contrast) and MRI are the mainstays for the diagnosis of NCC. When imaging was performed to look for anatomical causes, CT imaging revealed multiple hypodense lesions or cysts with calcifications in both the right frontal and parietal lobe, consistent with cysticercus cellulose. This was also reported by other case reports. MRI showed blurred cortical margins in the parietal region. Fourteen case reports showed scattered lesions all over the cerebrum.

### Antibody testing

Other tests that can be used to diagnose NCC are enzyme-linked electroimmunotransfer blot (EITB) as mentioned in...
previous case reports and enzyme-linked immunosorben
t assay (ELISA) test.22,23,29–31 The EITB has a sensitivity
ranging from 90% to 100% and a specificity of 100% in indi-
viduals with multiple cysterci, while the sensitivity drops
to 65% in patients with a single cyst.25 The ELISA test mea-
sures immunoglobulin G (IgG) antibodies against either the
somatic antigen or the excretory–secretory (ES) antigens.46
The sensitivity of the ELISA test for somatic antigen is 76%
in serum and 75% in CSF samples, while specificity is 97%
in serum and 96% in CSF.46 The sensitivity of the ELISA test
for ES antigen is 88% in serum and 64% in CSF, while spe-
cificity is 96% in serum and 97% in CSF.46

Treatment in case studies

The treatment modalities used to treat NCC psychosis in
our patient were albendazole, an antiparasitic and halop-
eridol, an antipsychotic. Similarly, albendazole was pre-
scribed in 11 out of the other 20 cases.12,13,18,20,22,23,24,29,41,47
Other medications used to treat NCC were dexamethasone
in 11 cases to reduce brain edema caused by perilesional
inflammation.12,18,20,22,23,29,41,47 Praziquantel was used in
three cases.26,28,40 Ventriculoperitoneal shunting was per-
formed to improve symptoms of hydrocephalus in three
cases.24,26,42

Although our patient was discharged with a complete
recovery similar to most other case reports, only one patient
succumbed to his illness in the intensive care unit (ICU) after
1 month of extensive treatment due to profuse cerebral
edema/diffuse global hypoxic ischemia.47 These treatments
mentioned above are effective against NCC. However, con-
tinuation may be difficult if the symptoms do not resolve
sooner or due to side effects associated with antipsychotic
medicines. Non-compliance is an essential factor to consider
for the recurrence of NCC in these patients. Non-compliance
can be attributed to the lower socio-economic status of some
of these patients rendering them incapable of acquiring
the recommended treatments. Several cases of NCC
psychosis have shown that long-term therapy, particularly
with antipsychotics (haloperidol, olanzapine, risperidone,
aripiprazole), continued for approximately 6 weeks to
22 months.2,3,22,26,28 When the treatment was interrupted for
any reason, the symptoms of psychosis resurfaced, resulting
in rehospitalizations for those individuals.2,3,22,26,28

Lesion localization and psychosis

Koropouli E et al.48 found a distinct region in the right rostral
tectum, near the lesion, whose activity is inversely connected
to the activity of the left amygdala, whereas the left amygd-
aala is functionally coupled with select areas of the temporal,
parietal and occipital lobes. Psychiatric disorders can occa-
sonally be linked to structural changes in the brain. Corpus
callosum lesions, in particular, appear to have a role in the
change in patients’ behavior. Pavesi G et al.49 described a case
of a rapid psychotic crisis caused by a hemorrhagic cavernous
angioma of the corpus callosum, which was surgically
excised and the symptoms were completely resolved. Al-
though a developmental abnormality such as agenesis or
lipoma is present in the majority of these instances, a devel-
op ing corpus callosum lesion is only rarely the underlying
cause. Clinicians should be aware of this link since it is pos-
sible to cure these people.

Barahona-Corrêa JB et al.50 collected 211 lesional mania
cases among 201 individuals with focal lesions, 60.7% had
lesions affecting just the right hemisphere, while 11.4% had
lesions involving only the left hemisphere. The right-sided
predominance of lesions was confirmed across multiple
brain regions, including the temporal lobe, fusiform gyrus
and thalamus, in additional analyses of 56 eligible lesion
images.

Recommendations

The literature indicates various antiepileptic drug (AED)
treatment durations. Two years of therapy with AED was
found to be similar to 1-year treatment in terms of rate of
seizure recurrence.51 Lesions caused by NCC take a long
time to calcify,52 AEDs are gradually tapered down through
incremental doses and eventually broken.53 Abrupt discon-
tinuation of AEDs is not recommended in patients with
multiple cysts as many would develop calcified lesions,
which increases the risk of repeated episodes of seizures.52
Although steroids have been used as an anti-inflammatory
to combat perilesional edema and inflammation, rebound
edema can commonly occur if steroids are not tapered
appropriately.54 Vesicular cysts are immune-tolerant and do
not degrade on their own with time, and increases the fre-
quency of seizures.55 Therefore, it is recommended to treat
with antiparasitic drugs as evidence suggests better outcomes
when compared to no treatment or placebos.56 The treatment
regimen for NCC is albendazole (15 mg/kg per day for
2 weeks) and praziquantel (50 mg/kg per day for 2 weeks),
which are the two most commonly used antiparasitic drugs,
with the former being more effective than the latter. Since
both these antiparasitic drugs have different mechanisms
of action, combining the two can increase the efficacy of treat-
ment. It has also been observed that treatment with albenda-
zole and praziquantel simultaneously increases the plasma
concentration of albendazole by 50%.56

It is also recommended that antiparasitic treatment is
not needed in patients with calcified lesions and NCC
encephalitis.43 Encephalitis is an inflammatory process, and
beginning antiparasitic treatment can exacerbate the inflam-
mation. Steroids and osmotic diuretics can be used to prevent
ICH.8 A craniotomy can decompress if medical treatment
fails.57

Conclusion

Diagnosis of NCC psychosis can be challenging despite
advances in neuroimaging and immunological diagnostic
Acknowledgement

The authors would like to thank Drs. Rizwan Ahmed and Zeenat Habibullah for their assistance with the literature search and manuscript preparation.

Author contributions

Dr S.A., Dr S.U., Dr S.J., Dr A.H., Dr Su.S., Dr A.H., S.M.S. and S.S. have been involved in the conception and design of the study, along with acquisition of data. All authors have participated in the drafting of the article and revising it critically for important intellectual content. All authors have provided final approval of the version to be submitted.

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article.

Ethical approval

Our institution does not require ethical approval for reporting individual cases or case series.

Funding

The author(s) received no financial support for the research, authorship and/or publication of this article.

Informed consent

Written informed consent was obtained from the patient(s) for their anonymized information to be published.

ORCID iD

Sadia Usmani https://orcid.org/0000-0002-0577-8562

References

1. World Health Organization. Taeniasis/cysticercosis, 2021, https://www.who.int/news-room/fact-sheets/detail/taeniasis-cysticercosis (accessed 4 March 2022)
2. Srivastava S, Chadda RK, Bala K, et al. A study of neuropsychiatric manifestations in patients of neurocysticercosis. Indian J Psychiatry 2013; 55(3): 264–267.
3. Coyle CM and Tanowitz HB. Diagnosis and treatment of neurocysticercosis. Interdiscip Perspect Infect Dis 2009; 2009: 180742.
4. CDC-Parasites Features Neurocysticercosis—CME, https://www.cdc.gov/parasites/features/ncc_cme_feature.html (accessed 4 March 2022)
5. Nikolić S and Stevanović G. [Neurocysticercosis—pathogenesis and clinical aspects]. Srp Arh Celok Lek 2006; 134(5–6): 246–250, http:// europepmc.org/abstract/MED/16972416
6. Mahajan SK, Machhan PC, Sood BR, et al. Neurocysticercosis presenting with psychosis. J Assoc Physicians India 2004; 52: 663–665.
7. NIMH Website. NIMH » What is Psychosis? National Institute of Mental Health, 2018, https://www.nimh.nih.gov/health/topics/schizophrenia/raise/what-is-psychosis (accessed 4 March 2022).
8. Fogang YF, Savadogo AA, Camara M, et al. Managing neurocysticercosis: challenges and solutions. Int J Gen Med 2015; 8: 333–344.
9. Mini-Mental State Examination Physioedia, https://www.physio-pedia.com/Mini-Mental_State_Examination (accessed 18 April 2022).
10. Mahendran R, Chua J, Feng L, et al. The mini-mental state examination and other neuropsychological assessment tools for detecting cognitive decline. In: Martin C and Preedy V (eds) Diet and Nutrition in Dementia and Cognitive Decline. New York: Elsevier, 2015, pp. 1159–1174.
11. Oyebode F. The neurology of psychosis. Med Princ Pract 2008; 17(4): 263–269.
12. Garieballa SS and Hakam AM. Neurocysticercosis presenting with psychiatric manifestations. Qatar Med J 2008; 17(2): 61–62.
13. Bhatia B, Mishra S and Srivastava AS. Neurocysticercosis presenting as schizophrenia: a case report. Indian J Psychiatry 1994; 36(4): 187–189.
14. Yildiz M, Borgwardt SJ and Berger GE. Parietal lobes in schizophrenia: do they matter? Schizophr Res Treatment 2011; 2011: 581686.
15. Bhushan A, Nain V, Singh P, et al. presenting with acute and transient psychotic disorder: a case report. Int J Curr Res 2020; 12(4): 10913–10914.
16. Gournellis R, Tournikioti K, Papanthasiou MA, et al. A case of neurocysticercosis: neuropsychiatric manifestations, course, and treatment. Indian J Psychiatry 2019; 61(5): 537–538.
17. Elemmamii A, Talyb S and Awad A. Neurocysticercosis presenting with psychosis. New Horizons Clin Case Reports 2017; 1: 23.
18. Reyazuddin M, Hussain K, Ibrahim A, et al. Acute psychosis: an unusual presentation in disseminated neurocysticercosis. Southeast Asian J Case Rep 2014; 3(6): 1191–1196.
19. de Almeida SM and Gurjão SA. Is the presence of depression independent from signs of disease activity in patients with neurocysticercosis? J Community Health 2011; 36(5): 693–697.
20. Sarangi R, Sahoo S and Mohapatra S. Neurocysticercosis masquerading psychotic disorder: a case report. J Acute Dis 2013; 2(1): 79–81.
21. Gripper LB and Welburn SC. The causal relationship between neurocysticercosis infection and the development of epilepsy—a systematic review. Infect Dis Poverty 2017; 6(1): 31.
22. Thapa DK, Limbu CP, Gurung A, et al. Neurocysticercosis presented with acute psychosis: a case report. Nepal J Neurosci 2016; 13(1): 54–56.

23. Anjana KK, Suresh V, Poornima C, et al. An unusual presentation of neurocysticercosis as psychosis with tics. Arch Ment Heal 2020; 21(1): 55–58.

24. Bourgeois JA, Motosue J and Mehra A. Mood and psychotic symptoms with neurocysticercosis. Psychosomatics 2002; 43(4): 337–338.

25. Wilson M, Bryan RT, Fried JA, et al. Clinical evaluation of the cysticercus enzyme-linked immunoelectrotransfer blot in patients with neurocysticercosis. J Infect Dis 1991; 164(5): 1007–1009.

26. Bills DC and Symon L. Cysticercosis producing various neurological presentations in a patient: case report. Br J Neurosurg 1992; 6(4): 365–369.

27. Del Brutto OH. Neurocysticercosis. Handb Clin Neurol 2014; 121: 1445–1459.

28. Shriqui CL and Milette PC. You drive me crazy: a case report of acute psychosis and neurocysticercosis. Can J Psychiatry 1992; 37(2): 121–124.

29. da Silva Miranda CC, Fernandes Dos Santos CFS and Cordeiro de Medeiros AB. Neurocysticercosis presenting as acute psychosis: an unusual case. Psychiatr Danub 2020; 32(3–4): 445–446.

30. Verma A and Kumar A. Neurocysticercosis presenting as acute psychosis: a rare case report from rural India. Asian J Psychiatr 2013; 6(6): 611–613.

31. Verma R, Anand KS, Chandra M, et al. Neurocysticercosis association with cognitive and aberrant behavioural symptoms: a case report and review. J Behav Brain Sci 2011; 1(4): 229–233.

32. Locker T, Mason S and Rigby A. Headache management—are we doing enough? An observational study of patients presenting with headache to the emergency department. Emerg Med J 2004; 21(3): 327–332.

33. Gotkine M, Kennedy PG and Steiner I. Post infectious CNS disorders: towards a unified approach. J Neurol 2010; 257(12): 1963–1969.

34. Del Brutto OH and Del Brutto VJ. Calcified neurocysticercosis among patients with primary headache. Cephalalgia 2012; 32(3): 250–254.

35. Forlenza OV, Filho AH, Nobrega JP, et al. Psychiatric manifestations of neurocysticercosis: a study of 38 patients from a neurology clinic in Brazil. J Neurol Neurosurg Psychiatry 1997; 62(6): 612–616.

36. Oglodek E, Szota A, Just M, et al. The role of the neuroendocrine and immune systems in the pathogenesis of depression. Pharmacol Rep 2014; 66(5): 776–781.

37. Bakunina N, Pariente CM and Zunszain PA. Immune mechanisms linked to depression via oxidative stress and neuroprogression. Immunology 2015; 144(3): 365–373.

38. Benatti C, Blom JM, Rigillo G, et al. Disease-induced neuroinflammation and depression. CNS Neurol Disord Drug Targets 2016; 15(4): 414–433.

39. Almeida SM and de Gurjão SA. Frequency of depression among patients with neurocysticercosis TT—Depressão em pacientes portadores de neurocisticercose. Arq Neuropsychiatr 2010; 68(1): 76–80, http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2010000100017

40. Mishra BN and Swain SP. Psychiatric morbidity following neurocysticercosis. Indian J Psychiatry 2004; 46(3): 267–278.

41. Singh S, Dhikav V, Agarwal N, et al. An unusual cause of psychosis. Lancet 2004; 363: P1522.

42. Fabiano Reis Lisiane Seguti L and de SQ. Racemose neurocysticercosis with psychiatric symptoms: a case report. J Neuroinfectious Dis 2015; 6(1): 163.

43. García HH, Nash TE and Del Brutto OH. Clinical symptoms, diagnosis, and treatment of neurocysticercosis. Lancet Neurol 2014; 13(12): 1202–1215.

44. Singh G, Rajeshkhar V, Murthy JMK, et al. A diagnostic and therapeutic scheme for a solitary cysticercus granuloma. Neurology 2010; 75: 2236–2245.

45. Agapevjev. Central nervous system agents in medicinal chemistry, https://benthamscience.com/journals/central-nervous-system-agents-in-medicinal-chemistry/ (accessed 4 March 2022).

46. Sahu PS, Parija SC, Narayan SK, et al. Evaluation of an IgG-ELISA strategy using Taenia solium metacestode somatic and excretory-secretory antigens for diagnosis of neurocysticercosis revealing biological stage of the larvae. Acta Trop 2009; 110(1): 38–45.

47. Mustafa N, Al Ayyat D, Awad M, et al. Neuropsychiatric Manifestations of Neurocysticercosis. Dubai Med J 2020; 3(1): 37–40, https://www.karger.com/DOI/10.1159/000506365

48. Koropouli E, Melanitis N, Dimitriou VI, et al. New-onset psychosis associated with a lesion localized in the rostral tectum: insights into pathway-specific connectivity disrupted in psychosis. Schizophr Bull 2020; 46(5): 1296–1305.

49. Pavesi G, Causin F and Feletti A. Cavernous angioma of the corpus callosum presenting with acute psychosis. Behav Neurol 2014; 2014: 243286.

50. Barahona-Corrêa JB, Cotovio G, Costa RM, et al. Right-sided brain lesions predominate among patients with leisonal mania: evidence from a systematic review and pooled lesion analysis. Transl Psychiatry 2020; 10(1): 139.

51. Singh PD, Dinakaran J, Khandelwal N, et al. One vs. two years of anti-epileptic therapy in children with single small enhancing CT lesions. J Trop Pediatr 2003; 49(5): 274–278.

52. Del Brutto OH. Prognostic factors for seizure recurrence after withdrawal of antiepileptic drugs in patients with neurocysticercosis. Neurology 1994; 44(9): 1706–1709.

53. Callaghan N, Garrett A and Goggin T. Withdrawal of anti-convulsant drugs in patients free of seizures for two years: a prospective study. N Engl J Med 1988; 318(15): 942–946.

54. Mejia R and Nash TE. Corticosteroid withdrawal precipitates seizures in patients with neurocysticercosis. Neurology 2014; 83(10): 1045–1048.

55. Zee CS, Go JL, Kim PE, et al. Imaging of neurocysticercosis. Neuroimaging Clin N Am 2000; 10(2): 391–407.

56. Garcia HH and Del Brutto OH; Cysticercosis Working Group in Peru. Neurocysticercosis: updated concepts about an old disease. Lancet Neurol 2005; 4(10): 653–661.

57. Del Brutto OH and Sotelo J. Neurocysticercosis: an update. Rev Infect Dis 1988; 10(6): 1075–1087.